Useless tests after initial screening for breast cancer are more likely in women who are, or were, taking hormone replacement therapy. Banks and colleagues (p 1291) reviewed data from more than 87 000 postmenopausal women screened in the NHS, and found that 3% of those with a negative screening had subsequent tests. Tests (and biopsies) were more likely in women still taking hormone replacement therapy and in past users.
